Compare AERT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | NEPH |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | Singapore | United States |
| Employees | 1400 | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 40.1M |
| IPO Year | N/A | 2004 |
| Metric | AERT | NEPH |
|---|---|---|
| Price | $7.29 | $3.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 385.1K | 9.1K |
| Earning Date | 02-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $340.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.26 | $2.66 |
| 52 Week High | $7.45 | $6.42 |
| Indicator | AERT | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 84.71 | 52.99 |
| Support Level | $0.45 | $2.77 |
| Resistance Level | $7.45 | $3.79 |
| Average True Range (ATR) | 0.52 | 0.23 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 92.27 | 56.15 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.